Gebro Pharma has signed a distribution agreement with Can-Fite BioPharma Ltd to distribute their lead drug candidate, Piclidenoson, for the treatment of rheumatoid arthritis and psoriasis in Spain, Switzerland and Austria, upon receipt of regulatory approvals.

"This agreement reinforces our portfolio in a strategic area for us, such as rheumatology. In addition, Can-Fite BioPharma has demonstrated solid capabilities to carry out development," explained Christian Kollenz, CEO at Gebro Pharma.

Can-Fite BioPharma Ltd is an Israeli biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases.

More information is available on the Gebro Pharma website and Can-Fite website.

Photo: The subsidiary of Gebro Pharma in Barcelona.